CN112042750A - 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 - Google Patents
一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 Download PDFInfo
- Publication number
- CN112042750A CN112042750A CN202010940024.0A CN202010940024A CN112042750A CN 112042750 A CN112042750 A CN 112042750A CN 202010940024 A CN202010940024 A CN 202010940024A CN 112042750 A CN112042750 A CN 112042750A
- Authority
- CN
- China
- Prior art keywords
- milk
- total
- powder
- infant formula
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 54
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 44
- 235000013336 milk Nutrition 0.000 title claims abstract description 31
- 239000008267 milk Substances 0.000 title claims abstract description 31
- 210000004080 milk Anatomy 0.000 title claims abstract description 31
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 16
- 108010071421 milk fat globule Proteins 0.000 title claims abstract description 13
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 10
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 10
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 9
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 32
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 32
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 32
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 32
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 32
- 229920000157 polyfructose Polymers 0.000 claims abstract description 23
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 17
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 17
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 11
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 11
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 11
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 11
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 11
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 10
- 150000003905 phosphatidylinositols Chemical class 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 7
- 229940067606 lecithin Drugs 0.000 claims abstract description 7
- 239000000787 lecithin Substances 0.000 claims abstract description 7
- 235000010445 lecithin Nutrition 0.000 claims abstract description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000002270 gangliosides Chemical class 0.000 claims abstract description 6
- 239000006041 probiotic Substances 0.000 claims abstract description 6
- 235000018291 probiotics Nutrition 0.000 claims abstract description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 17
- 108010046377 Whey Proteins Proteins 0.000 claims description 17
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 235000021119 whey protein Nutrition 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 10
- 108010063954 Mucins Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 102100039648 Lactadherin Human genes 0.000 claims description 7
- 101710191666 Lactadherin Proteins 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 210000003022 colostrum Anatomy 0.000 claims description 5
- 235000021277 colostrum Nutrition 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 101710186708 Agglutinin Proteins 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 101710146024 Horcolin Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 101710189395 Lectin Proteins 0.000 claims description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 239000000910 agglutinin Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 22
- 241000894006 Bacteria Species 0.000 abstract description 17
- 238000011161 development Methods 0.000 abstract description 10
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 235000020218 follow-on milk formula Nutrition 0.000 abstract description 2
- 229940088592 immunologic factor Drugs 0.000 abstract description 2
- 239000000367 immunologic factor Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 230000000813 microbial effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 150000004666 short chain fatty acids Chemical class 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 9
- 210000004251 human milk Anatomy 0.000 description 9
- 230000007358 intestinal barrier function Effects 0.000 description 9
- 102000015728 Mucins Human genes 0.000 description 8
- 235000021391 short chain fatty acids Nutrition 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 5
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- 230000007413 intestinal health Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000023011 digestive tract development Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000007296 Mucin-2 Human genes 0.000 description 3
- 108010008705 Mucin-2 Proteins 0.000 description 3
- 102000007270 Mucin-4 Human genes 0.000 description 3
- 108010008699 Mucin-4 Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940051875 mucins Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000722949 Apocynum Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000002029 Claudin Human genes 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010070158 Lactose synthase Proteins 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034242 Mucin-20 Human genes 0.000 description 1
- 101710155072 Mucin-20 Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- -1 ZO-1) (fig. 4A) Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 101150026564 gprs gene Proteins 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000204635 unclassified Bacteria Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C3/00—Preservation of milk or milk preparations
- A23C3/02—Preservation of milk or milk preparations by heating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明实施例涉及种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉,所述婴幼儿配方奶粉以生牛乳为原料、通过配方调整提升具有特殊功能成分的生物活性物质MFGM‑蛋白,乳铁蛋白(LF)、α‑乳白蛋白(α‑La)、总低聚半乳糖(GOS)、总多聚果糖、唾液酸、总磷脂、鞘磷脂(SM)、卵磷脂(PC)、磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)和磷脂酰肌醇(PI)、神经节苷脂(Gang)、甘油三职(TAG)、甘油二脂(DAG))的含量,达到促进婴儿肠道菌群中益生菌的定植尤其显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌,提高肠道中免疫因子的含量和降低肠道疾病发生率的目的,该配方适用于婴儿和较大婴儿配方乳粉的开发。
Description
技术领域
本发明涉及食品工程领域,尤其涉及一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法。
背景技术
分娩后婴儿的胃肠道结构和功能迅速适应从肠外营养(胎盘)向肠内营养(初乳/奶粉)的转变,在这个过程中并伴随着动态微生物定植。婴儿时期肠道微生物群的初步建立,参与肠道发育、代谢稳态和免疫防御多重相互作用,为以后长期健康奠定了关键基础。因此,新生儿肠道发育和微生物定植成为终生健康的窗口机会。由于出生后肠道微生态具有高度可塑性,在婴儿期易受营养摄入和周围环境的影响,宿主的健康生长需要优越的完整性和功能性肠道。此外,定植微生物群参与营养代谢,其代谢产物也有助于肠道屏障的完整性。因此,早期细菌最优定植影响了屏障功能,对肠道发育和新生儿生长起着至关重要的作用。
人乳是婴儿最理想的天然食物,已知人乳中有2000多种成分。人乳蛋白质也可以分为黏蛋白(mucins)、酪蛋白(casein)和乳清蛋白(whey)三组。黏蛋白也被称为乳脂肪球膜蛋白(milkfatglobulemembrane,MFGM),MFGM是一种包裹乳脂球的脂质-蛋白质复合物,对肠道消化、生理和调节微生物种群产生有利影响,有相关报道称其能加速婴幼儿和仔猪的生长发育。乳脂肪球膜的脂质主要由中性脂和极性脂,以及少量的糖脂构成。磷脂是一种极性脂,是脂质的主要组成部分,可以促进脂肪消化产物在消化道的吸收和转运,同时磷脂还参与机体免疫调节和神经信号转导等功能。人乳脂肪球中主要存在的磷脂包括鞘磷脂(SM)、卵磷脂(PC)、磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)和磷脂酰肌醇(PI)。乳脂肪球膜的中性脂如甘油三职(TAG)、甘油二脂(DAG)、胆固醇及其脂类。
低聚半乳糖(GOS)和多聚果糖(FOS)是宿主微生物选择性利用的益生元,赋予益生元在健康方面的作用。GOS和FOS的研究显示出对有益菌定殖的偏好,如乳酸菌,它对微生物菌群的代谢活性产生了与母乳低聚糖类似的影响。GOS和FOS在肠道发育和免疫应答方面也有很好的应用,GOS和FOS是肠道菌群发酵产生短链脂肪酸(short chain fatty acids,SCFAs)的益生元,对肠道的发育和生长具有有利作用。此外,源自牛奶的乳脂球膜(MFGM)在代谢调节和肠道稳态方面表现出营养生物活性。MFGM还能改变肠道菌群组成,增强肠道屏障功能。但婴儿期肠道发育和微生物定植是生长期的关键步骤,前人研究中关于MFGM研究和应用大多集中在组分分离、鉴定及通过代谢组学对其功能性质验证方面,但对婴儿肠道菌群定植、肠道微生态系统发育和屏障完整性的影响尚不清楚;GOS和MFGM干预的混合干预被报道可以改善仔猪的神经发育。但GOS、MFGM、FOS三者联合作用对肠道微生物组成和肠道发育的影响尚不明确。
发明内容
为解决现有技术问题,本发明的目的提供一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉。该奶粉以生牛乳为原料、填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成,通过配方调整提升具有特殊功能成分的生物活性物质MFGM-蛋白,乳铁蛋白(LF)、α-乳白蛋白(α-La)、总低聚半乳糖(GOS)、总多聚果糖(FOS)、唾液酸、总磷脂、鞘磷脂(SM)、卵磷脂(PC)、磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)和磷脂酰肌醇(PI)、神经节苷脂(Gang)、甘油三职(TAG)、甘油二脂(DAG))的含量,达到促进婴儿肠道菌群中益生菌的定植尤其显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌,提高肠道中免疫因子的含量和降低肠道疾病发生率的目的,该配方适用于婴儿和较大婴儿配方乳粉的开发。
本发明是通过下述技术方案实现的:
本发明提供一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉,以生牛乳为原料,填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成;其中每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.146-0.438g、总α-乳白蛋白0.22-0.35g、总乳铁蛋白0.2-0.6g、免疫球蛋白IgG0.1-0.3g、乳凝集素0.025-0.075g、MUC1/Mucin1 0.035-0.105g、总低聚半乳糖0.015-0.4g、总多聚果糖0.001-0.003g、唾液酸0.05-0.15g、总磷脂0.175-0.525g、神经鞘磷脂0.04-0.12g、神经节苷脂0.005-0.015g、卵磷脂0.06-0.19g、磷脂酰乙醇胺0.04-0.14g、磷脂酰肌醇0.02-0.06g、磷脂酰丝氨酸0.007-0.021g、甘油二脂0.0174-0.0371g、甘油三脂0.0311-0.0598g。见表1。
表1具有促进肠道健康的婴儿配方奶粉中功能活性成分的含量
上述婴幼儿配方奶粉,其中按照1吨婴幼儿配方奶粉计,富含MFGM的乳清蛋白粉的添加量25kg-75kg,α-乳白蛋白粉添加量8kg-75kg,低聚半乳糖添加量44kg-133kg和多聚果糖添加量1.8kg-5.5kg;牛初乳按照100L鲜奶制成15-16公斤牛初乳粉填加。按照上述比例填加调配出的婴幼儿配方奶粉具有较高的总α-乳白蛋白活性成分。
进一步优选,按照1吨婴幼儿配方奶粉计,富含MFGM的乳清蛋白粉的添加量55kg-65kg,α-乳白蛋白粉添加量8kg-15kg,低聚半乳糖添加量97kg-115kg和多聚果糖添加量4kg-5kg。
牛乳α-乳白蛋白与人乳的α-乳白蛋白只有76%的氨基酸序列一致,α-乳白蛋白对婴儿具有非常高的营养价值,其氨基酸组成非常类似于婴儿氨基酸需要量及氨基酸模式。已证明α-乳白蛋白是乳糖合成酶的一部分,在乳腺参与乳糖的合成。乳糖合成酶由两种蛋白质组成,即α-乳白蛋白和半乳糖基转移酶,它们共同催化葡萄糖与UDP-半乳糖的结合。α-乳白蛋白在婴儿肠道中被消化时,产生的多肽具有抗菌、增强婴儿免疫力的作用;最近发现的α-乳白蛋白多聚体也具有抗感染、促进细胞凋亡的作用,这些功能对保护婴儿肠道健康具有重要意义。本发明的配方中特别填加了α-乳白蛋白协同提高婴儿肠道健康的作用。
本发明上述婴幼儿配方奶粉中还可以添加其它配料如脂肪类、乳糖、矿物质、维生素及一些可选营养成分(胆碱、肌醇、牛磺酸、肉碱等)进行配料标准化后,调制出的婴儿配方乳粉具有促进婴儿肠道健康的作用。
本发明一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉的制备方法,包括如下步骤:以生牛乳作为原料乳,净乳后进行预杀菌(85℃-88℃,30s),向预杀菌的生牛乳中添加MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料,预杀菌(85℃-88℃,30s),均质15mPa,杀菌(93℃-95℃,15s),浓缩,喷雾干燥(进风温度150℃-160℃,出风温度85℃-90℃)即可。
本发明所述的产品营养指标、理化指标、微生物指标及感官指标的检测严格按照食品安全国家标准婴儿配方食品(GB-10765-2010)指定的检测项目及检验方法进行。
本发明另一个具体实施例是涉及一种利用高通量测序技术对仔猪粪便中16SrDNA基因进行测序分析,考察了本发明的配方奶粉对生长发育与肠道菌群构成的影响。
有益效果
本发明开发的具有促进婴儿肠道健康的配方乳粉,通过添加富含MFGM的乳清蛋白粉、α发乳白蛋白粉、低聚半乳糖和多聚果糖,提高配方中具有特殊功能作用的总MFGM-蛋白、低聚半乳糖、多聚果糖、乳铁蛋白、α-乳白蛋白、IgG、乳凝集素、MUC1/Mucin1、磷脂、神经节苷脂、神经鞘磷脂和唾液酸多种功能活性成分的含量,使其尽量接近于母乳。新生儿出生后,哺乳动物的肠道形态和功能必须适应从无菌子宫到细菌丰富的环境的转变,因此,新生儿期是微生物定植的关键窗口。通过仔猪模型实验,口服本发明配方能够改善仔猪生长性能和降低血浆IgG水平,激活仔猪肠道内益生菌定植,显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌。增强肠道屏障功能通过提高基因的表达紧密连接(Occludin和ZO-1),黏蛋白(Mucin-2和Mucin 4)和细胞因子(IL-1β和IL-22),增强肠道屏障功能,提高新生仔猪的生长性能。我们的研究结果将为GOS、MFGM和FOS在调节婴儿早期肠道微生态中起着非常重要的作用,该产品适用于婴儿及较大婴儿配方乳粉的开发。
附图说明
图1是本发明实施例1的新生仔猪第八天粪便菌群组成:
其中图A是多样性(Sobs指数);图B是香农指数(Shannon指数);图C是基于未加权Unifrac距离的PCoA的β多样性;图D是基于Wilconxon秩和检验的差异微生物组成;图E是属水平的线性别分析效应大小(LefSe)分析,线性判别分析(LDA)评分>4;*P<0.05;**P<0.01。
图2是本发明实施例1的新生仔猪第21天粪便菌群组成:
其中图A是多样性(Sobs指数);图B是香农指数(Shannon指数);图C是基于未加权Unifrac距离的PCoA的β多样性;图D是基于Wilconxon秩和检验的差异微生物组成;图E是属水平的线性别分析效应大小(LefSe)分析,线性判别分析(LDA)评分>4;*P<0.05;**P<0.01。
图3是本发明实施例1的新生仔猪肠道菌群功能状况:
其中图A为第八天京都基因和基因组百科全书(KEGG)的差异丰度;图B为第二十一天京都基因和基因组百科全书(KEGG)的差异丰度。
图4是本发明实施例1 21天新生仔猪肠道屏障相关基因表达和肠道通透性的影响:
肠屏障相关基因在回肠粘膜(A-C)和结肠粘膜(D-F)中的表达;血浆DAO水平表达(G)。
图5是本发明实施例1的仔猪粪便SCFAs浓度及肠道GPRs基因的影响:
其中仔猪粪便短链脂肪酸浓度差异(A)与受体基因表达(B)
图6是本发明实施例1的本发明的生产流程图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。除非另有其它明确表示,否则在整个说明书和权利要求书中,术语“包括”或其变换如“包含”或“包括有”等等将被理解为包括所陈述的元件或组成部分,而并未排除其它元件或其它组成部分。
实施例1婴儿配方奶粉中活性成分与母乳及对比例的比较,见表2
对比例:CN106359604A
表2
从上述比较可见,本发明的配方奶粉,活性成分更加全面接近母乳,尤其总α-乳白蛋白、卵磷脂、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰丝氨酸、甘油二脂、甘油三脂都是CN106359604A中不存在的成分。总乳铁蛋白要比对比例中高近10倍的量,与母乳减少差距。
表2中活性成分的按照下述方法调制而成,采用湿法加工工艺,图6所示。以生牛乳为原料乳,净乳后进行预杀菌,向预杀菌的生牛乳2000L中添加MFGM的乳清蛋白粉60kg、α-乳白蛋白粉10kg、低聚半乳糖106kg、多聚果糖4.33kg,均质,杀菌,浓缩,干燥即可。
上述方法中主要工艺参数为:所述预杀菌(85℃-88℃,30s);均质15mPa;杀菌(93℃-95℃,15s);喷雾干燥(进风温度150℃-160℃,出风温度85℃-90℃)。
本发明所述的产品营养指标、理化指标、微生物指标及感官指标的检测严格按照食品安全国家标准婴儿配方食品(GB-10765-2010)指定的检测项目及检验方法进行。实施例2基于仔猪模型对产品影响肠道微生态评价
1.试验方法
1.1基仔猪模型建立和样本采集
选择16只仔猪(1.53±0.04公斤)从不同的窝(每窝一个仔猪)被随机分配到对照组喂食生理盐水(简称CON组)和实验组喂食低聚半乳糖、MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖(简称GMF组本发明实施例1)。新出生第1天至第7天,GMF组的仔猪每天使用5mLGMF溶液(1g/kg体重),CON组仔猪饲喂等量生理盐水。在整个哺乳期,仔猪正常摄取母猪奶和水。商业饲料从产后第8天开始添加。每日监测健康状况,记录第21天的体重;第21天,选择5只仔猪(约为每组平均体重),并从颈静脉取样仔猪血样。在3000g下,在4℃下离心10分钟后,收集血浆。然后,收集粪便,并在液氮中快速冷冻,进行微生物组成分析。对仔猪安乐死后,将十二指肠、空肠和回肠标本固定在10%磷酸盐缓冲福尔马林中进行形态学评价。快速获得中柱和中柱的粘膜,并将其冷冻在液氮中进行基因表达鉴定。所有样品保存在-80℃,直到进一步分析。
1.2基于仔猪模型建立样本检测方法
1.2.1仔猪血浆样本检测
用ELISA方法测定仔猪血浆中二胺氧化酶(DAO)和免疫球蛋白(包括IgA、IgG和IgM)的含量。
1.2.2仔猪肠道微生态检测
从10%磷酸盐缓冲福尔马林液中取出肠道样品,通过分级乙醇系列(70%~100%)脱水,然后用二甲苯清除,并嵌入石蜡。连续切片(5μm厚),利用成像显微镜,测量了至少15个完整和定向良好的绒毛及其每个片段的相关隐窝放大率。从绒毛尖端到绒毛隐窝交界处测量绒毛高度,并将隐窝深度定义为相邻绒毛之间的内陷深度。
1.2.3仔猪粪便高通量16S rRNA测序
用引物扩增16SrRNA基因的V3-V4区域,并用Axy PrepDNA凝胶提取试剂盒纯化。然后,将纯化的PCR产物汇集成等摩尔量,在平台上测序。
1.2.4仔猪粪便短链脂肪酸的测定
用离子色谱仪对仔猪粪便样本中短链脂肪酸包括乙酸、丙酸和丁酸在内进行定量分析。
2.结果
2.1 GMF对仔猪生长发育影响
2.1.1 GMF对仔猪体重影响
如表3所示,与CON组仔猪重要相比,GMF组显著增加了第8天和第14天仔猪的体重(P<0.05)。此外,GMF组1-8、1-21日平均日增重和全周期(1-21日)均有显著升高(P<0.05)。
表3 MFGM和LF对于仔猪体重影响
2.1.2 GMF对仔猪血浆中IgG浓度影响
如表4可知,第21天仔猪血浆中IgG浓度在GMF喂养后显著升高(p<0.05),而Glu、IgA、IGM、TG、HDL-c和LDL-c等其他参数无差异。嗜乳脂蛋白(BTN)、粘蛋白(MUC)、黄黄嘌呤氧化还原酶(XOR)、乳黏素(MFG-E8)和脂肪酸结合蛋白(FABP)具有不同的生化特性。先前的研究表明,配方中的GMF补充剂对婴儿和动物的新生儿健康和肠道成熟具有促进生长的作用,本研究中血浆IgG水平的升高表明。
表4.MFGM和LF对于仔猪第21天的血浆影响
2.1.3 GMF对仔猪肠形态道发育影响
为了确定仔猪的肠道形态发育,测定了仔猪的绒毛高度和隐窝深度(表5)。结果表明,GMF组可明显提高十二指肠和回肠的绒毛高度,而降低十二指肠隐窝深度(p<0.05)。
表5.MFGM对于仔猪第21天的肠道微生态影响
2.2 GMF对于仔猪肠道菌群影响
为了研究CON和GMF两组仔猪早期菌群的差异,采用16S rRNA高通量测序技术对其微生物多样性、组成及差异进行了评价。
2.2.1仔猪菌群构成
仔猪出生第8天粪便菌群如图1所示,α-多样性指数分析显示GMF组多样性(Sobs)指数明显下降(P<0.05)(图1A),而香农指数不改变(图1B);β-多样性,PCoA分析显示CON组和GMF组之间差异显著(图1C);从菌群构成的角度,仔猪的差异菌群表明,GMF可以显著富集乳酸菌,减少未分类菌科(P<0.05)(图1D)。线性判别分析效应量(LEfSe)分析也证实GMF组仔猪乳酸菌显著升高(图1E)。
仔猪出生第21天粪便菌群如图2所示,α-多样性,图2A和图2B显示GMF组多样性(Sobs)指数和香农指数显著增加;β-多样性,PCoA分析显示CON组与GMF组之间存在显著差异(图2C);在菌属水平上菌群差异显示(图2D拟杆菌、肠球菌、克里斯滕森菌和罗布西亚菌呈现增加趋势,而真杆菌属成员呈现下降趋势;线性判别分析效应量(LEfSe)分析显示(图2E)GMF组的拟杆菌、肠球菌、罗布西亚菌、g_反刍动物科_UCG-002、g_克里斯滕森_R-7_group、g_马文步里安提亚科、g_CHKCI001和未分类菌属在GMF组呈现显著上升趋势。
2.2.2仔猪菌群功能
为了进一步探索细菌群落的功能概况,我们利用KEGG数据库,通过PICRUSt,对群落进行系统发育研究。如图3A所示,第8天,GMF增加了糖酵解/糖异生作用、甘油脂代谢、MAPK信号通路、内噬作用、类黄酮生物合成、咖啡因代谢显著升高,而与卟啉和叶绿素代谢、氮代谢相关的基因降低。图3B第21天,GMF干预显著富集了甲烷代谢、精氨酸和脯氨酸代谢、氧化磷酸化、苯丙氨酸、酪氨酸和色氨酸生物合成、丁酸盐代谢、脂质生物合成蛋白、丙酸盐代谢、缬氨酸、亮氨酸和异亮氨酸降解、β-丙氨酸代谢、苯丙氨酸代谢、色氨酸代谢、RNA聚合酶、柠檬烯和蒎烯降解,但与其他离子偶联转运体和其他转运体连接的基因下降。
2.3 GMF对仔猪肠道功能影响
2.3.1仔猪肠道屏障功能
为明确肠屏障功能和肠通透性,检测肠屏障相关基因在黏膜(回肠和结肠)和血浆DAO水平的表达。仔猪回肠紧密连接蛋白(E-钙黏着蛋白、ZO-1)(图4A)、粘蛋白(黏蛋白-1、黏蛋白-2、黏蛋白-4)(图4B)、IL-22(图4C)基因表达在GMF组中显著升高(P<0.05)。同样,仔猪结肠中紧密连接蛋白的基因表达(封堵器表达,连接蛋白-1和ZO-1)(图4D),黏蛋白-20(图4E)和细胞因子(TNF-α和IL-1β)(图4F)在GMF组中显著升高(P<0.05)。GMF组血浆DAO水平显著降低(P<0.05)(图4G)。
2.3.2仔猪粪便SCFAs浓度以及受体基因表达
仔猪粪便中SCFAs的浓度及其在肠道中的受体基因表达。结果表明,GMF组乙酸、丙酸和丁酸的浓度均显著高于CON组(p<0.05)(图5A)此外,GMF组增加了GPR41在结肠粘膜中的基因表达(图5B)。GMF组短链脂肪酸浓度及其受体(GPR41)升高促进了丙酸代谢,调节益生菌定植和短链脂肪酸代谢,最终激活了肠细胞,增强了肠道屏障功能。
综上所述,通过仔猪模型实验可知,口服GMF(低聚半乳糖、α-乳白蛋白粉、MFGM蛋白乳清粉和多聚果糖)仔猪可以显著提高生长性能和降低血浆IgG水平,出生后一周产生了益生菌定植(乳酸菌、肠球菌和罗布西亚菌),促进了短链脂肪酸的产生,增强肠道屏障功能通过提高基因的表达紧密连接(封堵器蛋白和ZO-1),黏蛋白(黏蛋白-2和黏蛋白-4)和细胞因子(IL-1β和IL-22),因此提高仔猪的生长性能在整个新生儿期。我们的研究结果将为低聚半乳糖、α-乳白蛋白粉、乳脂肪球膜蛋白和多聚果糖在调节婴儿早期肠道微生态中起着非常重要的作用。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉,其特征在于,所述婴幼儿配方奶粉以生牛乳为原料、填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成,其中每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.146-0.438g、总α-乳白蛋白0.22-0.35g、总乳铁蛋白0.2-0.6g、免疫球蛋白IgG0.1-0.3g、乳凝集素0.025-0.075g、MUC1/Mucin1 0.035-0.105g、总低聚半乳糖0.015-0.4g、总多聚果糖0.001-0.003g、唾液酸0.05-0.15g、总磷脂0.175-0.525g、神经鞘磷脂0.04-0.12g、神经节苷脂0.005-0.015g、卵磷脂0.06-0.19g、磷脂酰乙醇胺0.04-0.14g、磷脂酰肌醇0.02-0.06g、磷脂酰丝氨酸0.007-0.021g、甘油二脂0.0174-0.0371g、甘油三脂0.0311-0.0598g。
2.如权利要求1所述的婴幼儿配方奶粉,其特征在于,所述的每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.438g、总α-乳白蛋白0.35g、总乳铁蛋白0.35g、免疫球蛋白IgG0.172g、乳凝集素0.075g、MUC1/Mucin1 0.105g、总低聚半乳糖0.4g、总多聚果糖0.003g、唾液酸0.15g、总磷脂0.525g、神经鞘磷脂0.12g、神经节苷脂0.015g、卵磷脂0.19g、磷脂酰乙醇胺0.14g、磷脂酰肌醇0.06g、磷脂酰丝氨酸0.021g、甘油二脂0.0371g、甘油三脂0.0598g。
3.如权利要求1所述的婴幼儿配方奶粉,其特征在于,按照1吨婴幼儿配方奶粉计,富含MFGM的乳清蛋白粉的添加量25kg-75kg,α-乳白蛋白粉添加量8kg-20kg,低聚半乳糖添加量44kg-133kg和多聚果糖添加量1.8kg-5.5kg;优选,按照1吨婴幼儿配方奶粉计富含MFGM的乳清蛋白粉的添加量55kg-65kg,α-乳白蛋白粉添加量7kg-15kg,低聚半乳糖添加量97kg-115kg和多聚果糖添加量4kg-5kg。
4.如权利要求1所述的婴幼儿配方奶粉,其特征在于,牛初乳按照100L鲜奶制成15-16公斤牛初乳粉填加。
5.如权利要求1-4任意一项所述的婴幼儿配方奶粉,其特征在于,按照生牛乳每2000L中添加MFGM的乳清蛋白粉60kg、α-乳白蛋白粉10kg、低聚半乳糖106kg、多聚果糖4.33kg。
6.如权利要求1所述的婴幼儿配方奶粉,其特征在于,所述的婴幼儿配方奶粉是通过下述方法调制而成的:以生牛乳作为原料乳,净乳后进行预杀菌85℃-88℃,30s,向预杀菌的生牛乳中添加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料,预杀菌85℃-88℃,30s,均质15mPa,杀菌93℃-95℃,15s,浓缩,喷雾干燥进风温度150℃-160℃,出风温度85℃-90℃即可。
7.如权利要求1所述的婴幼儿配方奶粉的制备方法,其特征在于,包括如下步骤:以生牛乳作为原料乳,净乳后进行预杀菌,向预杀菌的生牛乳中添加MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料,预杀菌,均质,杀菌,浓缩,喷雾干燥即可。
8.如权利要求7所述的婴幼儿配方奶粉的制备方法,其特征在于,所述预杀菌85℃-88℃,30s,均质条件15mPa,杀菌93℃-95℃,15s,喷雾干燥:进风温度150℃-160℃,出风温度85℃-90℃。
9.如权利要求1所述的婴幼儿配方奶粉在制备促进婴幼儿肠道益生菌富集的食品中的应用。
10.如权利要求1所述的婴幼儿配方奶粉在制备提高婴幼儿免疫力食品中的应用。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010940024.0A CN112042750B (zh) | 2020-09-09 | 2020-09-09 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
AU2021340764A AU2021340764B2 (en) | 2020-09-09 | 2021-08-23 | Infant formula milk powder rich in milk fat globule membrane protein, phospholipid and oligosaccharide, and preparation method therefor |
PCT/CN2021/113937 WO2022052794A1 (zh) | 2020-09-09 | 2021-08-23 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
US18/172,992 US20230263179A1 (en) | 2020-09-09 | 2023-02-22 | Infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides and preparation method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010940024.0A CN112042750B (zh) | 2020-09-09 | 2020-09-09 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112042750A true CN112042750A (zh) | 2020-12-08 |
CN112042750B CN112042750B (zh) | 2022-04-05 |
Family
ID=73609864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010940024.0A Active CN112042750B (zh) | 2020-09-09 | 2020-09-09 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230263179A1 (zh) |
CN (1) | CN112042750B (zh) |
AU (1) | AU2021340764B2 (zh) |
WO (1) | WO2022052794A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022052794A1 (zh) * | 2020-09-09 | 2022-03-17 | 北京三元食品股份有限公司 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
CN117378762A (zh) * | 2023-12-12 | 2024-01-12 | 内蒙古伊利实业集团股份有限公司 | 一种影响海马体中纤维束丰富程度的营养组合物及其应用 |
CN117378763A (zh) * | 2023-12-12 | 2024-01-12 | 内蒙古伊利实业集团股份有限公司 | 具有免疫调节功能活性的营养组合物及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115191509B (zh) * | 2022-07-04 | 2023-09-26 | 江南大学 | 一种具有润肠通便功能的中老年雪糕 |
CN116649420B (zh) * | 2023-06-05 | 2024-05-24 | 高培(广州)乳业有限公司 | 一种营养益智、易消化吸收的营养奶粉及其制备方法 |
CN116616348B (zh) * | 2023-07-21 | 2023-11-14 | 美赞臣婴幼儿营养品技术(广州)有限公司 | 含唾液酸的组合物及其在益生菌增殖和调节免疫中的应用 |
CN117652567B (zh) * | 2024-02-02 | 2024-04-12 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种儿童配方牛奶及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101484024A (zh) * | 2006-06-30 | 2009-07-15 | 艾博特公司 | 富集的婴儿配方 |
CN101636167A (zh) * | 2006-12-28 | 2010-01-27 | 明治乳业株式会社 | 含有乳来源的磷脂的婴幼儿脑发育促进剂以及含有该促进剂的食品组合物 |
CN102524422A (zh) * | 2012-02-22 | 2012-07-04 | 浙江康恩贝健康产品有限公司 | 含α-乳白蛋白和乳铁蛋白的婴幼儿配方奶粉及制备方法 |
CN102665428A (zh) * | 2009-12-08 | 2012-09-12 | 雀巢产品技术援助有限公司 | 含有益生菌和乳脂肪球膜组分的婴儿配方 |
CN103596440A (zh) * | 2011-06-08 | 2014-02-19 | 雀巢产品技术援助有限公司 | 含有外源性乳脂肪球膜组分的营养组合物 |
US20150237902A1 (en) * | 2012-09-11 | 2015-08-27 | Nucitec, S.A. De C.V. | Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants |
CN105744845A (zh) * | 2013-11-29 | 2016-07-06 | 雀巢产品技术援助有限公司 | 具有磷脂的营养组合物 |
CN106359604A (zh) * | 2016-08-24 | 2017-02-01 | 北京三元食品股份有限公司 | 一种促进肠道健康的婴儿配方乳粉及其制备方法 |
CN106857855A (zh) * | 2016-12-19 | 2017-06-20 | 北京三元食品股份有限公司 | 一种富含乳脂肪球膜和结构脂opo的婴儿配方乳粉及其制备方法 |
CN109007037A (zh) * | 2018-10-16 | 2018-12-18 | 北京斯利安药业有限公司 | 一种增强婴幼儿免疫力的组合物及其产品与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE537951C2 (sv) * | 2013-07-01 | 2015-12-01 | Hero Ag | Profylaktisk användning av modersmjölksersättning mot otit |
US20180133287A1 (en) * | 2016-11-14 | 2018-05-17 | Mead Johnson Nutrition Company | Nutritional compositions providing dietary management of colic |
US20180160714A1 (en) * | 2016-12-12 | 2018-06-14 | Mead Johnson Nutrition Company | Nutritional compositions containing butyrate and uses thereof |
CN106912614A (zh) * | 2017-03-10 | 2017-07-04 | 海普诺凯营养品有限公司 | 一种母乳化配方奶粉及其制作方法 |
CN108294112B (zh) * | 2018-01-12 | 2021-08-06 | 雅士利国际婴幼儿营养品有限公司 | 优化蛋白质和氨基酸模式的婴儿配方奶粉及其制备方法 |
CN110477129A (zh) * | 2019-09-14 | 2019-11-22 | 李钟� | 一种富含乳脂球膜蛋白及磷脂的婴儿配方乳粉 |
CN112042750B (zh) * | 2020-09-09 | 2022-04-05 | 北京三元食品股份有限公司 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
-
2020
- 2020-09-09 CN CN202010940024.0A patent/CN112042750B/zh active Active
-
2021
- 2021-08-23 WO PCT/CN2021/113937 patent/WO2022052794A1/zh active Application Filing
- 2021-08-23 AU AU2021340764A patent/AU2021340764B2/en active Active
-
2023
- 2023-02-22 US US18/172,992 patent/US20230263179A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101484024A (zh) * | 2006-06-30 | 2009-07-15 | 艾博特公司 | 富集的婴儿配方 |
CN101636167A (zh) * | 2006-12-28 | 2010-01-27 | 明治乳业株式会社 | 含有乳来源的磷脂的婴幼儿脑发育促进剂以及含有该促进剂的食品组合物 |
CN102665428A (zh) * | 2009-12-08 | 2012-09-12 | 雀巢产品技术援助有限公司 | 含有益生菌和乳脂肪球膜组分的婴儿配方 |
CN103596440A (zh) * | 2011-06-08 | 2014-02-19 | 雀巢产品技术援助有限公司 | 含有外源性乳脂肪球膜组分的营养组合物 |
CN102524422A (zh) * | 2012-02-22 | 2012-07-04 | 浙江康恩贝健康产品有限公司 | 含α-乳白蛋白和乳铁蛋白的婴幼儿配方奶粉及制备方法 |
US20150237902A1 (en) * | 2012-09-11 | 2015-08-27 | Nucitec, S.A. De C.V. | Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants |
CN105744845A (zh) * | 2013-11-29 | 2016-07-06 | 雀巢产品技术援助有限公司 | 具有磷脂的营养组合物 |
CN106359604A (zh) * | 2016-08-24 | 2017-02-01 | 北京三元食品股份有限公司 | 一种促进肠道健康的婴儿配方乳粉及其制备方法 |
CN106857855A (zh) * | 2016-12-19 | 2017-06-20 | 北京三元食品股份有限公司 | 一种富含乳脂肪球膜和结构脂opo的婴儿配方乳粉及其制备方法 |
CN109007037A (zh) * | 2018-10-16 | 2018-12-18 | 北京斯利安药业有限公司 | 一种增强婴幼儿免疫力的组合物及其产品与应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022052794A1 (zh) * | 2020-09-09 | 2022-03-17 | 北京三元食品股份有限公司 | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 |
CN117378762A (zh) * | 2023-12-12 | 2024-01-12 | 内蒙古伊利实业集团股份有限公司 | 一种影响海马体中纤维束丰富程度的营养组合物及其应用 |
CN117378763A (zh) * | 2023-12-12 | 2024-01-12 | 内蒙古伊利实业集团股份有限公司 | 具有免疫调节功能活性的营养组合物及其应用 |
CN117378763B (zh) * | 2023-12-12 | 2024-03-26 | 内蒙古伊利实业集团股份有限公司 | 具有免疫调节功能活性的营养组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20230263179A1 (en) | 2023-08-24 |
AU2021340764A1 (en) | 2022-06-23 |
WO2022052794A1 (zh) | 2022-03-17 |
CN112042750B (zh) | 2022-04-05 |
AU2021340764B2 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112042750B (zh) | 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 | |
Brink et al. | Milk fat globule membrane: the role of its various components in infant health and development | |
JP6158380B2 (ja) | 小腸に良い栄養組成物 | |
Playne et al. | Functional dairy foods and ingredients | |
EP3209308B1 (en) | Activated bifidobacteria and methods of use thereof | |
JP6234227B2 (ja) | 腸内菌叢改善用栄養組成物 | |
EP2440217B1 (en) | Nutrition for improving muscle strength in elderly | |
del Carmen Tocaa et al. | Lactose intolerance: myths and facts. An update | |
JP2016531114A (ja) | 腫瘍の成長を阻止する栄養組成物 | |
JP5951087B2 (ja) | インフルエンザ感染症の予防組成物 | |
TW201729824A (zh) | 用於促進腸道屏障功能並減緩內臟疼痛之營養組成物 | |
WO2015199192A1 (ja) | グレリン分泌促進剤 | |
CN103429092A (zh) | 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途 | |
JP6773562B2 (ja) | スフィンゴ脂質吸収促進剤 | |
BR112019012965A2 (pt) | uso de bactérias do ácido láctico para tratar ou prevenir diabetes mellitus gestacional | |
Li et al. | Tibetan Plateau yak milk: A comprehensive review of nutritional values, health benefits, and processing technology | |
WO2011099875A1 (en) | Use of lactic acid bacteria to treat or prevent rhinitis | |
Tiwari et al. | Nutritional Values and Therapeutic Uses of Capra hircus Milk. | |
RU2682257C2 (ru) | Лактоферрин, улучшение памяти и повышение скорости обучения у детей | |
CN112205476A (zh) | β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用 | |
WO2017126645A1 (ja) | エンドトキシンの血中移行阻害用組成物 | |
Soleymanzadeh Moghadam et al. | Does Probiotic Therapy Have Effect on Serum Calcium and Cholesterol Levels in Demyelinated Hippocampus? | |
Shama | Human Milk-based Protein Concentrate Supports Growth of Weanling Rats | |
Moghadam et al. | Does Probiotic Therapy Have Effect on Serum Calcium and Cholesterol Levels in Demyelinated Hippocampus? | |
CN117481201A (zh) | 一种促进大脑发育的配方奶粉及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |